Amit Hasija - 02 Feb 2026 Form 4/A - Amendment Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Reporting relationship: CFO & EVP of Corp. Development
Issuer ticker: MIST
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 05 Feb 2026, 16:30:12 UTC
Original report date: 04 Feb 2026
Prior SEC filing: 28 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Oliveto, Attorney-in-Fact

Key filing fact

Amit Hasija filed Form 4/A - Amendment for Milestone Pharmaceuticals Inc. (MIST) on 05 Feb 2026.

Key facts

This page summarizes Amit Hasija's Form 4/A - Amendment filing for Milestone Pharmaceuticals Inc. (MIST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2026, 16:30.

Change

Previous filing in this sequence was filed on 28 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001787700 Primary reporting owner

Hasija Amit

Relationship: CFO & EVP of Corp. Development
Address: C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA
Signature: /s/ Joseph Oliveto, Attorney-in-Fact
Signature date: 05 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIST transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +204,000
Change %
Price: $0.000000
Shares after: 204,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 204,000
Exercise price: $1.96
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price on the initial filings was incorrectly stated.

Footnote F2

One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.